This is a routine board change with no immediate trading implications. Monitor for any future equity issuances tied to the new director's compensation milestones, but no near-term catalyst is present.
Price Chart
Executive Summary
Propanc Biopharma reported the retirement of independent director Annie Van Broekhoven and the appointment of Carlo Campiciano as her replacement, effective July 8, 2026. The new director brings accounting and corporate finance experience from MedAdvisor Limited. The change is a routine board refresh with no material financial implications.
Key Facts
- Annie Van Broekhoven retired from the Board effective July 8, 2026.
- Carlo Campiciano was appointed as an independent director on the same date.
- Mr. Campiciano is a qualified accountant with experience as CFO of MedAdvisor Limited (ASX).
- Cash compensation is $45,000 per annum paid quarterly.
- Equity compensation may range from 0.5% to 4.99% based on company milestones.
Financial Impact
No material financial impact; director compensation is $45,000 per annum with potential equity grants up to 4.99%.
Risk Factors
- Potential dilution from future equity grants to the new director, though capped at 4.99% and tied to milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-033173 |
| Document: form8-k.htm | 0001493152-26-033173 |
| Document: 0001493152-26-033173-index-headers.html | 0001493152-26-033173 |
| Document: 0001493152-26-033173-index.html | 0001493152-26-033173 |
| Document: 0001493152-26-033173.txt | 0001493152-26-033173 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | — |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | — |
Sep 29, 2026 27d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | — |
Aug 18, 2026 9w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | — |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | — |
May 19, 2026 22w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | — |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | — |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | — |
Apr 21, 2026 26w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | — |
Mar 24, 2026 30w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers